Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03465540 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies
A Phase 1 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT03465540 is a Phase 1 study that was terminated before completion, run by Amgen. The registered enrollment target is 24 participants.
The verdict
NCT03465540, a Phase 1 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
Evaluate the safety and tolerability of AMG 397. Estimate the maximum tolerated doses (MTDs) and/or biologically active doses.
Interventions
- DRUG Azacitidine
- DRUG Dexamethasone
- DRUG AMG 397
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2018-08-17 |
| Est. Completion | 2019-07-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03465540
The ClinicalTrials.gov registry entry for NCT03465540 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Azacitidine is the first listed.
NCT03465540 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03465540 about?
NCT03465540 is a clinical study titled "Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies". Evaluate the safety and tolerability of AMG 397. Estimate the maximum tolerated doses (MTDs) and/or biologically active doses.
What is the current status of trial NCT03465540?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2018-08-17. Estimated completion is 2019-07-25.
What interventions are being tested in trial NCT03465540?
The interventions under investigation include: Azacitidine (DRUG), Dexamethasone (DRUG), AMG 397 (DRUG).
Who is sponsoring clinical trial NCT03465540?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.